A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6

Hughes, Brett G. M.;Guminski, Alexander;Bowyer, Samantha;Migden, Michael R.;Schmults, Chrysalyne D.;Khushalani, Nikhil I.;Chang, Anne Lynn S.;Grob, Jean-Jacques;Lewis, Karl D.;Ansstas, George;Day, Fiona;Ladwa, Rahul;Stein, Brian N.;Muñoz Couselo, Eva;Meier, Friedegund;Hauschild, Axel;Schadendorf, Dirk;Basset-Seguin, Nicole;Modi, Badri;Dalac-Rat, Sophie;Dunn, Lara A.;Flatz, Lukas;Mortier, Laurent;Guégan, Sarah;Heinzerling, Lucie M.;Mehnert, Janice M.;Trabelsi, Sabiha;Soria-Rivas, Ainara;Stratigos, Alexander J.;Ulrich, Claas;Wong, Deborah J.;Beylot-Barry, Marie;Bossi, Paolo;Bugés Sánchez, Cristina;Chandra, Sunandana;Robert, Caroline;Russell, Jeffery S.;Silk, Ann W.;Booth, Jocelyn;Yoo, Suk-Young;Seebach, Frank;Lowy, Israel;Fury, Matthew G.;Rischin, Danny

2025-01-01